Swiss National Bank lifted its stake in shares of Insulet Co. (NASDAQ:PODD) by 2.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 110,300 shares of the medical instruments supplier’s stock after purchasing an additional 2,600 shares during the quarter. Swiss National Bank owned about 0.18% of Insulet worth $13,168,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Manchester Capital Management LLC purchased a new stake in shares of Insulet in the 1st quarter worth about $31,000. Meridian Wealth Management LLC purchased a new stake in shares of Insulet in the 1st quarter worth about $48,000. Quadrant Capital Group LLC boosted its position in shares of Insulet by 1,037.7% in the 1st quarter. Quadrant Capital Group LLC now owns 603 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 550 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of Insulet in the 2nd quarter worth about $119,000. Finally, Flagship Harbor Advisors LLC boosted its position in shares of Insulet by 8.6% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 1,577 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 125 shares in the last quarter.
Several equities research analysts recently commented on the stock. Guggenheim boosted their price objective on shares of Insulet from $100.00 to $145.00 and gave the stock a “positive” rating in a research report on Tuesday, August 6th. Northland Securities lowered shares of Insulet from an “outperform” rating to a “market perform” rating and set a $100.00 price objective on the stock. in a research report on Monday, June 10th. Morgan Stanley boosted their price objective on shares of Insulet from $127.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 6th. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Finally, JPMorgan Chase & Co. upgraded shares of Insulet from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $120.00 to $155.00 in a research report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $131.71.
NASDAQ:PODD opened at $154.09 on Friday. The firm has a market cap of $9.28 billion, a price-to-earnings ratio of 3,081.80 and a beta of 1.08. The company has a current ratio of 4.72, a quick ratio of 3.91 and a debt-to-equity ratio of 2.43. The company’s 50-day moving average is $132.04 and its two-hundred day moving average is $107.18. Insulet Co. has a 12-month low of $70.80 and a 12-month high of $158.18.
Insulet (NASDAQ:PODD) last released its earnings results on Monday, August 5th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.01). The firm had revenue of $177.10 million during the quarter, compared to analysts’ expectations of $163.63 million. Insulet had a net margin of 2.66% and a return on equity of 7.85%. Insulet’s revenue for the quarter was up 42.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.03) earnings per share. On average, equities research analysts forecast that Insulet Co. will post 0.26 earnings per share for the current fiscal year.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Featured Story: What is a balanced fund?
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.